Arvinas (ARVN) Competitors

Arvinas (NASDAQ:ARVN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Do analysts rate ARVN or ACAD?

Arvinas currently has a consensus target price of $34.33, suggesting a potential upside of 374.87%. ACADIA Pharmaceuticals has a consensus target price of $23.87, suggesting a potential upside of 63.81%. Given Arvinas' stronger consensus rating and higher probable upside, equities analysts plainly believe Arvinas is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.69
ACADIA Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has more volatility and risk, ARVN or ACAD?

Arvinas has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Is ARVN or ACAD more profitable?

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Arvinas' net margin of -75.51%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-75.51%	-33.75%	-16.75%
ACADIA Pharmaceuticals	13.83%	25.83%	14.71%

Does the MarketBeat Community believe in ARVN or ACAD?

ACADIA Pharmaceuticals received 702 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 73.09% of users gave ACADIA Pharmaceuticals an outperform vote while only 66.55% of users gave Arvinas an outperform vote.

Company	Underperform	Outperform
Arvinas	Outperform Votes 197 66.55%	Underperform Votes 99 33.45%
ACADIA Pharmaceuticals	Outperform Votes 899 73.09%	Underperform Votes 331 26.91%

Which has higher valuation & earnings, ARVN or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$263.40M	1.89	-$198.90M	-$2.77	-2.61
ACADIA Pharmaceuticals	$957.80M	2.54	-$61.29M	$1.36	10.71

Do insiders & institutionals have more ownership in ARVN or ACAD?

95.2% of Arvinas shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 5.2% of Arvinas shares are held by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media favor ARVN or ACAD?

In the previous week, Arvinas and Arvinas both had 17 articles in the media. Arvinas' average media sentiment score of 0.90 beat ACADIA Pharmaceuticals' score of 0.50 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	6 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats Arvinas on 12 of the 17 factors compared between the two stocks.